Significant Progress Made in Advancing Company’s Small Molecules for the Treatment of Autoimmune Diseases; Appoints Chairman of the Board and Welcomes New Vice President in Preparation for Clinic Ann Arbor, Mich., and Cambridge, Mass. – April 28, 2010 — Lycera Corporation, a biopharmaceutical company pioneering an innovative approach to developing novel oral medicines to treat… Read More

Former Head of U.S. Commercial at Biogen Idec Will Lead Emerging Small Molecule Immunology Company in Next Phase of Growth Ann Arbor, Mich., and Cambridge, Mass. – January 7, 2010 — Lycera Corporation, a pharmaceutical company focused on developing novel small-molecule medicines to treat autoimmune diseases, today announced that William J. Sibold has been named… Read More

ANN ARBOR, Mich., October 9, 2009 — Lycera Corp., which is developing novel small-molecule pharmaceuticals to treat autoimmune diseases, today announced the appointments of Paul S. Changelian, Ph.D. and Peter L. Toogood, Ph.D. to the company’s drug development team. Dr. Changelian, previously director of inflammation biology at Pfizer, will serve as vice president of biology.… Read More

ANN ARBOR, Mich., August, 18 2009 — Lycera Corp. today announced the appointment of five accomplished scientists and clinicians to its Scientific Advisory Board. The company, which recently announced a $36 million Series A financing, is developing novel small-molecule pharmaceuticals to treat autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease. “Each of these… Read More

ANN ARBOR, Mich., July 29, 2009 —Lycera Corp. today announced that Robert Kamen, Ph.D., biotech consultant and past president of Abbott Bioresearch Center will join the company’s Board of Directors. Lycera, which recently announced a $36 million Series A financing, is developing novel small-molecule pharmaceuticals to treat autoimmune diseases such as rheumatoid arthritis and inflammatory… Read More

ANN ARBOR, Mich., April 16, 2009 — Lycera Corp. today announced it has closed a $36 million Series A financing. The company, which is developing novel small-molecule pharmaceuticals to treat autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease, has received $10 million as a first tranche of the financing and will receive the… Read More

ANN ARBOR, Mich., August 4, 2008 — Lycera Corporation today announced that it entered into a licensing agreement with a leading specialty pharmaceutical company in the United States to develop and commercialize a series of novel small molecules for the topical treatment of human dermal conditions, including mild to moderate psoriasis. According to the National… Read More

ANN ARBOR, Michigan – EDF Ventures today announced the successful completion of venture funding for Lycera Corporation, a pharmaceutical research and development company created in August 2006. The financing was led by EDF Ventures with the participation of a select group of experienced east coast angel investors. Lycera is developing breakthrough small molecule drugs for the treatment of diseases characterized… Read More